The well-known difference in mean pressure readings between DCT and GAT was not affected by the increase in CCT following DSAEK. IOP readings with the GAT seem not to be influenced by the increase in CCT. Because of the remarkable differences in individual pairs of IOP measurements, both GAT and DCT should be used after DSAEK.

The mean cutting depth for the DSAEK keratomes is more accurate than the cutting depth of the same keratome heads designed for LASIK. This might be due to the fact that DSAEK lamellas were cut after complete epithelial removal. Despite the accurate mean cutting accuracy, there is a substantial variation between individual cuts which have to be taken into consideration.

Unlike the cup/disc ratio, which focuses on the excavation, the DDLS is based directly on the thickness of the neuroretinal rim and takes into account the optic disc size. Therefore, the DDLS estimates the glaucomatous damage of the optic disc more precisely than the currently used method. Although this new grading system is more complicated to use in clinical practice, the interobserver agreement for the DDLS in our study setting was very good.

BackgroundExcessive wound healing, with scarring of the episcleral tissue or encapsulation of the filtering bleb is the main reason for failure in trabeculectomy. Ranibizumab, an inhibitor of the Vascular Endothelial Growth Factor (VEGF), is seen as a promising candidate to prevent or treat extensive wound healing. We describe the design of a two phased study, i) assessing the local tolerability and safety of topical ranibizumab and ii) assessing the efficacy of topical ranibizumab against placebo in patients who underwent trabeculectomy with mitomycin C combined with phacoemulsification and intra ocular lens (IOL) implantation.Methods/DesignIn the first phase five patients that had trabeculectomy with mitomycin C combined with phacoemulsification and IOL implantation will be treated with topical ranibizumab (Lucentis®) eye drops (2 mg/ml) four times daily for one month. The treatment will be started at the first postoperative day. Patients will be assessed for local and systemic side effects using a standardised schedule. In the second phase, after successful completion of phase 1, consenting eligible patients who underwent trabeculectomy with mitomycin C combined with phacoemulsification and IOL implantation will be randomised to either receive topical ranibizumab eye drops (2 mg/ml) four times daily for 1 month or placebo (BSS 4x/d for 1 month). Patients will be reviewed weekly for 4 weeks until conjunctival sutures are removed. Further follow up examinations are planned after 3 and six months. Assessment of differences in the intraocular eye pressure will be considered primary, and bleb appearance/vascularisation using a standardized photography and the Moorfields bleb grading system, postoperative intraocular pressure and conjunctival wound healing problems will be considered secondary outcome parameters.DiscussionAnti-VEGF-antibodies might be more effective in preventing scaring and might have fewer toxic side effects than the currently used anti-metabolites and may replace them in the long term.Trial RegistrationISRCTN: ISRCTN12125882

KP in FHUS cause a focal damage of endothelial cells reflected in a decreased percentage of healthy hexagonal cells. The degree of endothelial cell damage seems to be low as it does not lead to a significant reduction in the endothelial cell count.